GDF15 Antibody

What is GDF15 and what are its key biological functions?

GDF15, also known as macrophage inhibitory cytokine 1 (MIC-1), is a stress-responsive cytokine that functions in multiple biological processes. Mature human GDF15 is a disulfide-linked homodimer of the carboxy-terminal 112 amino acid residues . It has been shown to inhibit tumor necrosis factor alpha (TNF-alpha) production from lipopolysaccharide-stimulated macrophages, induce cartilage formation, promote early-stage endochondral bone formation, and enhance neuronal survival . Additionally, GDF15 plays crucial roles in cancer-related immunosuppression, metabolic regulation, and inflammatory responses .

What methods are available for detecting GDF15 in experimental settings?

Multiple validated methods exist for GDF15 detection:

Western Blot Applications:

• Recommended dilution: 1:5000-1:50000

• Expected molecular weight: ~34 kDa under reducing conditions, though bands at ~35 kDa and ~47 kDa have been reported in different cell lines

• Successfully detected in: HT-1080 cells, HepG2 cells, human placenta tissue, and LNCaP cells

Immunohistochemistry (IHC):

• Recommended dilution: 1:50-1:500

• Suggested antigen retrieval: TE buffer pH 9.0 or citrate buffer pH 6.0

• Successfully detected in: human placenta tissue

ELISA and Other Methods:

• Indirect ELISA using His-tagged GDF15 protein as coating antigen

• Molecular Interaction Analyzer (Fortebio, OCTETRED96E) for binding kinetics

• Functional reporter assays using HEK293 SRE-luc2-cRET-GFRAL cells

How do polyclonal and monoclonal GDF15 antibodies differ in research applications?

Polyclonal antibodies like Proteintech's 27455-1-AP recognize multiple epitopes on GDF15, offering high sensitivity but potential variability between lots . Monoclonal antibodies provide consistent epitope recognition, critical for therapeutic applications like visugromab (CTL-002) in clinical trials .

For research requiring detection of different forms of GDF15 (precursor vs. mature), polyclonal antibodies may offer advantages. Conversely, neutralization studies typically benefit from monoclonal antibodies' consistent epitope binding. When selecting between these options, researchers should consider:

What controls are essential when evaluating GDF15 neutralizing antibody effectiveness?

When evaluating GDF15 neutralizing antibodies, rigorous controls are essential:

• Isotype controls: Use antibodies raised against irrelevant antigens (e.g., keyhole limpet hemocyanin as in murine studies)

• Dose-response assessments: Test gradient dilutions of antibodies co-incubated with fixed concentrations of GDF15 protein to establish effective neutralization ranges

• Cell-based functional assays: Employ reporter cell lines like HEK293 SRE-Luc2-cRET-GFRAL that respond to GDF15 signaling

• Molecular validation: Verify disruption of GDF15-GFRAL binding using techniques like ELISA blocking experiments

• Signaling pathway verification: Confirm inhibition of downstream signaling events through measurement of reporter gene activation or phosphorylation status of pathway components

One effective approach is the dual validation strategy demonstrated by Xiong et al., where they validated their KY-NAb-GDF15 antibody using both ELISA blocking experiments and cell-based reporter assays with consistent GDF15 concentrations (5 ng/mL) and antibody dilutions from 1 μg/mL .

How should researchers optimize GDF15 antibody concentration for different experimental systems?

Optimization strategies vary by application:

For Western Blotting:
Start with manufacturer's recommended dilution ranges (e.g., 1:5000-1:50000 for Proteintech 27455-1-AP) and adjust based on protein abundance in your specific samples. For HT-1080 fibrosarcoma cells, 0.5 μg/mL has proven effective .

For Neutralization Studies:

• Begin with co-incubation of antibody at 0.1-1 μg/mL with GDF15 protein at physiologically relevant concentrations (5 ng/mL for in vitro studies)

• Assess dose-response relationships by keeping GDF15 concentration fixed while titrating antibody concentration

• Alternate approach: Fix antibody concentration (e.g., 0.1 ng/mL) and vary GDF15 concentration to determine the saturation point

For Immunohistochemistry:
Start with 1:50-1:500 dilution range and optimize based on tissue type and fixation method . Antigen retrieval with TE buffer pH 9.0 improves detection in placental tissues .

What methodological considerations are important when developing a GDF15 neutralizing antibody?

Development of effective GDF15 neutralizing antibodies requires careful consideration of:

• Immunization strategy: The approach used by Xiong et al. involved dividing BALB/c mice into three groups for immunization via different routes (intramuscular, intraperitoneal, and subcutaneous), with each immunization comprising 10 μg of GDF15 protein mixed with aqueous adjuvant . Serum titer monitoring is crucial, with positive titers identified when OD450 nm > 2 compared to negative serum .

• Fusion and screening methods: Effective hybridoma generation involves fusion of spleen cells from immunized mice with SP2/0 myeloma cells through electrofusion, followed by screening in HAT medium using ELISA .

• Epitope selection: Target epitopes that interfere with the GDF15-GFRAL interaction for neutralizing antibodies, as this disrupts downstream RET-mediated signaling .

• Species cross-reactivity assessment: Consider that mature human GDF15 shares only 66.1% and 68.7% amino acid sequence similarity with rat and mouse GDF15, respectively, which are remarkably low homologies between species in the TGF-beta superfamily . This may impact antibody cross-reactivity for in vivo studies.

• Functional validation: Utilize reporter cell systems (like HEK293 SRE-luc2-cRET-GFRAL) that monitor GDF15-driven interactions of RET with GFRAL on the cell surface .

How does GDF15 contribute to immunosuppression in cancer, and how can antibodies counteract this effect?

GDF15 promotes tumor immunosuppression through multiple mechanisms:

• Inhibition of T cell trafficking: GDF15 inhibits LFA-1 activation on CD8+ T cells, interfering with effector T cell recruitment to tumor tissues . This mechanism creates "immune-excluded" tumors where T cells cannot effectively infiltrate.

• Regulatory T cell (Treg) enhancement: GDF15 promotes the generation of peripherally derived inducible Treg cells and enhances the suppressive function of natural Treg cells by interacting with the CD48 receptor on T cells . This interaction downregulates STUB1, an E3 ligase that mediates forkhead box P3 (FOXP3) protein degradation, thereby stabilizing FOXP3 and enhancing Treg function .

• Reduced FOXP3 ubiquitination: GDF15 decreases FOXP3 ubiquitination in both human and mouse naïve CD4+ T cells and primary nTreg cells, which increases FOXP3 stability and enhances immunosuppressive function .

Neutralizing antibodies counteract these effects by:

• Restoring T cell infiltration into tumors by preventing GDF15-mediated inhibition of the LFA-1/ICAM-1 cell adhesion axis

• Reducing regulatory T cell generation and function by allowing normal FOXP3 degradation

• Reversing resistance to immune checkpoint inhibitors like anti-PD-1 antibodies

These mechanisms explain why GDF15 neutralizing antibodies like visugromab (CTL-002) show promise in clinical trials when combined with anti-PD-1 therapy for patients with anti-PD-1/PD-L1 refractory cancers .

What is known about the receptors for GDF15 and how do they affect antibody targeting strategies?

Research has identified multiple receptors for GDF15, which influences antibody development strategies:

• GFRAL-RET complex: The canonical GDF15 receptor in metabolic regulation is GFRAL (GDNF-family receptor α-like) coupled with RET (Rearranged during Transfection) co-receptor . This complex mediates effects on weight loss and cachexia.

• CD48 receptor: Recently identified as a GDF15 receptor on T cells, CD48 mediates immunosuppressive effects by regulating FOXP3 stability in regulatory T cells . This represents "the first discovered receptor of GDF15 in the immune system" .

These distinct receptors create opportunities for targeted antibody development:

How does GDF15 influence metabolic regulation during inflammation, and what implications does this have for antibody-based interventions?

GDF15 coordinates metabolic adaptation during inflammation through:

• Hepatic sympathetic outflow: GDF15 is required for maintaining hepatic sympathetic nervous system activity during inflammation .

• Triglyceride metabolism: GDF15 regulates triglyceride production, which supports the metabolic demands of the heart and prevents cardiac damage during inflammatory stress .

• Disease tolerance mechanisms: GDF15 promotes survival during inflammation independently of pathogen control, suggesting a role in disease tolerance rather than resistance . In various inflammatory models (bacterial, viral, sepsis), GDF15 neutralization increased mortality without affecting pathogen burden .

• Cardiac and renal protection: GDF15's metabolic effects provide cardioprotection and renoprotection during inflammatory stress, as evidenced by increased cardiac damage markers (troponin I) and renal injury markers (BUN) in animals treated with GDF15-neutralizing antibodies during inflammation .

These findings have important implications for antibody-based interventions:

• Cautionary approach in inflammatory settings: GDF15 neutralization may be detrimental during acute inflammation or infection, potentially compromising tissue tolerance to inflammatory damage .

• Therapeutic window considerations: The timing of GDF15 neutralization may be critical, with different effects during acute versus chronic inflammation.

• Combined metabolic support: When using GDF15-neutralizing antibodies in inflammatory contexts, supporting triglyceride metabolism through exogenous lipid administration might mitigate adverse effects .

• Monitoring cardiac function: Close monitoring of cardiac parameters may be necessary when using GDF15-neutralizing antibodies, particularly in patients with pre-existing cardiac conditions.

How can GDF15 antibodies be utilized in cancer immunotherapy research, particularly in relation to immune checkpoint inhibitor resistance?

GDF15 antibodies offer promising approaches for addressing immune checkpoint inhibitor resistance:

• Combination therapy models: Preclinical research demonstrates that GDF15 blockade synergistically enhances anti-PD-1 checkpoint inhibition efficacy . The GDFATHER-1/2a clinical trial (NCT04725474) is evaluating the efficacy of visugromab (anti-GDF15) plus nivolumab (anti-PD-1) in patients with checkpoint inhibitor-refractory cancers .

• Patient selection biomarkers: Researchers identified non-squamous non-small cell lung cancer and urothelial cancer as frequently immunosuppressed by GDF15 through in silico screening of approximately 10,000 tumor samples in The Cancer Genome Atlas database . This suggests GDF15 expression could serve as a biomarker for selecting patients likely to benefit from anti-GDF15 therapy.

• Immune response assessment: Key parameters for monitoring anti-GDF15 efficacy include:

  • Tumor infiltration by T cells (increases with successful GDF15 neutralization)

  • T cell proliferation in tumor tissue

  • Interferon-γ-related signaling

  • Granzyme B expression by cytotoxic T cells

• Serial tumor biopsy models: The GDFATHER trial incorporates serial tumor biopsies to evaluate pharmacodynamic effects of GDF15 neutralization, including changes in immune cell composition within tumor tissue .

This research direction is particularly relevant as "durable and deep responses were achieved in some patients with non-squamous non-small cell lung cancer and urothelial cancer" using anti-GDF15 combined with anti-PD-1 therapy .

What are the implications of GDF15 neutralization for cachexia research in cancer and other chronic diseases?

GDF15 neutralization has significant implications for cachexia research:

• Cancer cachexia models: GDF15 neutralizing antibodies like KY-NAb-GDF15 show promise in alleviating cancer-induced cachexia . These antibodies target the GFRAL-RET signaling pathway through which GDF15 induces weight loss .

• Chemotherapy-induced weight loss: GDF15 neutralization may mitigate chemotherapy-induced weight loss, as GDF15 has been identified as "a major causative factor of chemotherapy-induced cachexia" .

• Specificity of GDF15 effects: Research has found that the effects of GDF15 neutralization differ by context. In inflammatory sepsis models, GDF15 neutralization with mAB2 did not prevent or exacerbate LPS-induced anorexia, weight loss, or mortality, suggesting context-specific roles .

• Pre-exposure sensitization hypothesis: Individuals with thalassemia who exhibit chronically high levels of GDF15 show reduced incidence of nausea/vomiting during pregnancy, suggesting a desensitization mechanism in GDF15 receptors. This principle could inform strategies for managing chemotherapy-induced nausea and weight loss .

• Comprehensive endpoints: When designing cachexia intervention studies with GDF15 antibodies, researchers should include:

  • Body weight measurements

  • Food intake monitoring

  • Body composition analysis (lean vs. fat mass)

  • Energy expenditure assessment

  • Muscle function tests

  • Inflammatory markers

  • Quality of life measures

How are GDF15 antibodies being applied to study nausea and vomiting mechanisms in pregnancy and chemotherapy?

Research into GDF15's role in nausea and vomiting presents novel applications for GDF15 antibodies:

• Pregnancy-related nausea models: GDF15 has been identified as "the likely dominant cause of nausea and vomiting in pregnancy (NVP)" . In experimental mouse models, neutralizing antibodies against GDF15 have effectively prevented nausea and vomiting .

• Chemotherapy-induced nausea: Administration of platinum-based chemotherapy agents results in notable increases in GDF15 levels. In experimental mouse models, neutralizing antibodies against GDF15 have prevented chemotherapy-induced nausea and vomiting .

• Receptor desensitization studies: The observation that individuals with thalassemia (who have chronically high GDF15 levels) show reduced NVP suggests a desensitization mechanism in hindbrain GDF15 receptors . This creates research opportunities for studying receptor sensitization/desensitization using antibodies to modulate GDF15 exposure.

• Cross-disease comparison models: There are noteworthy parallels between pregnancy-related and chemotherapy-induced nausea/vomiting in terms of GDF15 involvement. Antibody studies could elucidate shared mechanisms and therapeutic approaches .

• GDF15 knockout validation: Studies using GDF15 knockout mice that do not produce the peptide have shown no signs of nausea/vomiting in response to stimuli that typically induce these symptoms . This validates the essential role of GDF15 and supports the potential efficacy of neutralizing antibodies.

Commercial development of GDF15 antibodies for this indication could lead to therapeutic options within the next decade, with significant implications for both pregnancy-related nausea and chemotherapy-induced nausea and vomiting .

What are common challenges in detecting GDF15 using antibodies, and how can they be addressed?

Researchers frequently encounter challenges when detecting GDF15:

• Multiple molecular weight forms: GDF15 appears at different molecular weights depending on the cell type and detection method. In Western blots, bands have been reported at approximately 35 kDa in HT1080 human fibrosarcoma cells under reducing conditions , while Simple Western analysis detected GDF15 at approximately 47 kDa in the same cell line . This variation reflects different forms of GDF15 (precursor vs. mature) and potential post-translational modifications.

  Solution: Use positive control samples (HT1080 or HepG2 cells) with known GDF15 expression patterns and consider running gels under both reducing and non-reducing conditions to identify different forms.

• Species cross-reactivity limitations: Mature human GDF15 shares only 66.1% and 68.7% amino acid sequence similarity with rat and mouse GDF15 respectively, which are "remarkably low homologies between species in TGF-beta superfamily" .

  Solution: Verify antibody cross-reactivity before conducting cross-species studies. For in vivo studies in animal models, consider species-specific antibodies or validating human-reactive antibodies for cross-reactivity.

• Appropriate buffer selection: Buffer conditions can significantly impact detection sensitivity.

  Solution: For Western blotting, Immunoblot Buffer Group 1 has been successfully used for GDF15 detection . For antigen retrieval in IHC, TE buffer pH 9.0 is recommended, though citrate buffer pH 6.0 can serve as an alternative .

• Secreted vs. intracellular GDF15: As GDF15 is a secreted protein, detection strategies may differ for cell lysates versus conditioned media.

  Solution: For comprehensive analysis, examine both cellular and secreted fractions, using appropriate sample preparation for each compartment.

How should researchers interpret conflicting data regarding GDF15 function in different disease models?

The literature contains apparent contradictions regarding GDF15 function:

• Protective vs. pathological roles:

  • In inflammatory models, GDF15 neutralization increased mortality, suggesting a protective role

  • In cancer models, GDF15 neutralization improved outcomes, indicating a pathological role

  Interpretation approach: Consider context-specific effects. GDF15 appears to promote tolerance to acute inflammatory damage while contributing to immunosuppression in cancer contexts. These seemingly contradictory roles reflect GDF15's evolutionary adaptation to different physiological challenges.

• Contradictory antibody study outcomes:

  • One study found that anti-GDF15 antibody increased mortality in sepsis models without impacting food intake

  • Another study reported GDF15 knockout mice had increased survival in the CLP mouse sepsis model

  Interpretation approach: Evaluate antibody specificity, timing of intervention, and genetic compensation in knockout models. Acute neutralization versus genetic deletion may yield different outcomes due to developmental adaptation or compensatory mechanisms.

• Receptor engagement disparities:

  • Some effects appear mediated through GFRAL-RET signaling (metabolic)

  • Others involve CD48 receptor engagement (immune)

  Interpretation approach: Design experiments to specifically assess which receptor system mediates observed effects. Use receptor-specific blocking approaches or cell types with differential receptor expression.

When facing conflicting data, adopt these methodological strategies:

• Standardize experimental conditions across models

• Use multiple antibody clones targeting different epitopes

• Include appropriate genetic models (knockout, conditional knockout)

• Consider tissue-specific and temporal factors in GDF15 signaling

What are the important considerations for translating preclinical findings with GDF15 antibodies to clinical applications?

Translating preclinical findings to clinical applications requires careful consideration of:

• Target population selection:

  • Identify tumor types with GDF15-mediated immunosuppression (e.g., non-squamous non-small cell lung cancer and urothelial cancer)

  • Focus on patients with anti-PD-1/PD-L1 refractory disease, as they may benefit most from combined GDF15 neutralization

• Biomarker development:

  • Establish baseline GDF15 levels that predict response to anti-GDF15 therapy

  • Develop pharmacodynamic markers of effective GDF15 neutralization

  • Monitor immune cell infiltration and activation in tumor tissue through serial biopsies

• Dosing and schedule optimization:

  • Consider the pharmacokinetics and tissue penetration of antibodies

  • Evaluate different sequencing approaches (concurrent vs. sequential administration of anti-GDF15 and anti-PD-1)

  • Determine optimal treatment duration based on sustained immune activation

• Safety monitoring:

  • Given GDF15's protective role in inflammation , monitor for potential exacerbation of inflammatory conditions

  • Assess cardiac function, as GDF15 neutralization may impact cardiac protection during inflammatory stress

  • Consider potential metabolic effects, particularly on triglyceride metabolism and energy homeostasis

• Combination strategy development:

  • Beyond anti-PD-1 combinations, explore synergies with other immunotherapies or conventional treatments

  • Investigate potential for triplet combinations targeting multiple immune checkpoints

The GDFATHER-1/2a trial (NCT04725474) provides a model for clinical translation, incorporating patient selection, serial biopsies, and careful monitoring of immune parameters as key elements of study design .